Byline: Industry Desk, Health Metrics Review

Date: October 26, 2023

LONDON – The Body Mass Index, a 190-year-old mathematical formula that has silently governed clinical obesity diagnosis, insurance premiums, and public health policy across the globe, is facing an existential reckoning. At the European Congress on Obesity (ECO) in Dublin this week, a coalition of 58 endocrinology, cardiology, and primary care societies released a joint position paper calling for a “fundamental restructuring” of how adiposity is measured in clinical settings. The paper, titled“Beyond BMI: A Framework for Functional Adiposity Assessment,”stops short of demanding a total abolition, but it signals a decisive shift in the industry’s consensus.

The core contention is not new: BMI (weight in kilograms divided by height in meters squared) fails to distinguish between muscle mass, bone density, and visceral fat. It systematically misclassifies athletes as “overweight” and, more dangerously, labels a significant portion of metabolically unhealthy individuals with normal weight as “healthy.” What is new, however, is the scale of institutional backing and the emergence of a viable alternative: the Waist-to-Height Ratio (WHtR), which the paper proposes as a first-line screening tool alongside BMI, rather than a replacement.

The Dublin Consensus: A Two-Tier Diagnostic Model

According to the draft guidelines seen by BMI News, the proposed model would use WHtR (waist circumference divided by height, with a cutoff of 0.5) as the initial risk stratification. Patients above the 0.5 threshold would then undergo a secondary assessment—either via DEXA scan for body fat percentage or a bioelectrical impedance analysis—before a formal obesity diagnosis is made. BMI would remain in use only as a population-level epidemiological metric, not for individual clinical decisions.

“The problem is not that BMI is useless; it is that we have treated a crude correlation as a causal law,” said Dr. Helena Voss, a metabolic physician at University College London and lead author of the position paper, in an exclusive interview with BMI News. “A 2023 meta-analysis of 72 cohorts involving 1.1 million adults showed that WHtR outperforms BMI in predicting all-cause mortality and cardiovascular events by approximately 18% in men and 22% in women. We are ignoring a cheap, tape-measure-based tool that costs pennies, while we continue to rely on a number that tells us nothing about fat distribution.”

The industry response has been swift. The International Federation for the Surgery of Obesity (IFSO) issued a cautious endorsement, noting that surgical eligibility criteria—historically tied to a BMI of 35 or 40—would need recalibration. Meanwhile, the American Medical Association (AMA) has already taken a more aggressive stance. In a policy update published in September, the AMA formally recognized BMI as “an imperfect measure” and urged physicians to use it “in conjunction with other valid measures of risk such as waist circumference, skinfold thickness, and dual-energy x-ray absorptiometry (DEXA).”

Insurance and Pharma: The Economic Earthquake

The financial implications of this shift are substantial. Global health insurers have historically used BMI thresholds to deny coverage for bariatric surgery, GLP-1 receptor agonist prescriptions, and even fertility treatments. If WHtR becomes the new gatekeeper, the eligible population for these interventions could expand by an estimated 25–30% in Western markets, according to a preliminary actuarial analysis by the consultancy HealthValue Group.

“The immediate losers are not patients—they are the actuarial tables,” said Marcus Feld, a senior healthcare analyst at Berenberg Bank, speaking at the Dublin conference. “We are looking at a scenario where a 5-foot-6 woman weighing 150 pounds with a 35-inch waist is reclassified from ‘normal weight’ to ‘high-risk central obesity.’ That is a woman who currently cannot get a GLP-1 prescription reimbursed in most U.S. plans. Under the new framework, she would be first in line. The cost pressure on payers is enormous.”

Pharmaceutical companies, notably Novo Nordisk and Eli Lilly, have been quietly funding research into alternative metrics for years. Internal documents from a major trial of semaglutide (Wegovy) show that while the trials used BMI for enrollment, the primary endpoint for cardiovascular outcomes was actually driven by changes in waist circumference. Industry insiders suggest that a move to WHtR would actually favor these drugs, as they produce significant reductions in visceral fat even in patients with modest BMI changes.

The Pediatric Frontier: Where the Debate Gets Heated

The most contentious arena is pediatric medicine. In the United States, BMI-for-age percentiles are the standard for identifying childhood obesity, and they are embedded in federal school health programs. The new position paper argues that WHtR is particularly valuable in children because it tracks central fat accumulation during puberty, which BMI fails to capture.

“We see a 14-year-old boy with a BMI in the 60th percentile—he looks ‘normal’ on the growth chart. But his waist-to-height ratio is 0.55. He has what we call ‘thin-outside, fat-inside’ phenotype. He is at high risk for insulin resistance, yet no school nurse, no pediatrician, no insurance algorithm flags him,” said Dr. Priya Raghavan, a pediatric endocrinologist at the Hospital for Sick Children in Toronto, who was not directly involved in the Dublin paper but co-authored a rebuttal commentary published inThe Lancet Diabetes & Endocrinologythis week. “The resistance to change is not scientific; it is bureaucratic. Changing BMI charts means changing electronic health records, changing school screening software, changing 40 years of training materials. That is a multi-billion-dollar administrative cost.”

Her rebuttal, which argues for a “hybrid approach” using BMI for baseline and WHtR for dynamic monitoring, was met with a sharp response from the Dublin authors, who called it “a compromise that perpetuates diagnostic delay.”

Regulatory and Technological Tailwinds

On the regulatory front, the U.S. Food and Drug Administration (FDA) has not yet updated its guidance for obesity drug development, which still requires BMI as a primary inclusion criterion. However, the FDA’s 2023 draft guidance on “Patient-Focused Drug Development for Obesity” includes language suggesting that “alternative anthropometric measures may be considered as secondary endpoints.” The European Medicines Agency (EMA) is expected to issue a similar reflection paper by Q2 2024.

Technology is accelerating the transition. Consumer wearable makers—Apple, Smart Scales, and newer entrants like Smart Scales—have begun integrating waist-to-height ratio calculations into their health apps using smart scales that measure body composition. The latest Smart Scales Body Scan, released in September, automatically calculates WHtR and flags users above 0.5, pushing the metric into mainstream consumer consciousness. This is significant: a 2022 survey by the International Food Information Council found that 61% of U.S. adults could correctly identify their BMI, but only 12% had ever heard of WHtR. That gap is closing rapidly.

The Skeptics’ Last Stand

Not everyone is convinced. A vocal minority of statisticians argues that WHtR has its own flaws—it is less standardized across ethnic groups (the 0.5 cutoff is based largely on European data), and waist measurement is prone to inter-observer variability. Dr. Jonas Lindqvist, a biostatistician at Karolinska Institute, told BMI News: “We are trading one crude tool for another. WHtR is better, but it is not good. The real future is MRI-based visceral fat quantification, which is now feasible with accelerated scanning protocols. The problem is cost and access. Until that is solved, we are arguing over which imperfect proxy to use.”

Despite this, the momentum is undeniable. The Dublin position paper will be formally voted on by the European Association for the Study of Obesity (EASO) in November. If passed, it will become the official standard for 45 member societies. The World Health Organization (WHO) has scheduled a technical consultation on “Anthropometric Indicators for the 21st Century” for March 2024, with WHtR on the agenda as an official review item.

What This Means for the Next Decade

Industry observers predict a gradual, messy transition. Electronic health record vendors (Epic, Cerner) have already announced that their 2024 software updates will include automated WHtR calculation and flagging. Major pharmacy chains in the UK and Canada have begun offering free waist measuring tape at prescription counters, a low-cost marketing move that normalizes the metric.

For the average person, the change may feel subtle: a doctor’s visit that used to end with “Your BMI is 27, let’s talk about weight” may soon end with “Your waist-to-height ratio is 0.53, let’s talk about visceral fat.” The language shifts from a moralistic number to a physical measurement. For clinicians, the shift represents a return to bedside examination over algorithmic convenience.

As Dr. Voss concluded in her keynote address: “We did not invent WHtR to be trendy. We are simply acknowledging that a tape measure around the waist, combined with a height measurement, tells us more about a person’s metabolic future than a formula derived in 1832 from a Belgian astronomer’s study of Scottish and French soldiers. The industry has known this for 30 years